suMMARY Anticoagulant treatment reduces the risk of embolic and thrombotic complications in certain patients but haemorrhagic problems of the treatment have been less critically assessed. In this study 501 fully documented outpatients treated between 1970 and 1977, comprising 1199 patient-years of treatment, have been analysed in an attempt to clarify the iatrogenic risks of haemorrhage associated with oral anticoagulants.
The coumarin group of anticoagulants was developed by Link in the late 1930's (Link, 1943 (Link, -1944 and their use in man first reported by Butt et al. in 1941. Since then they have been used to reduce the risk of embolic and thrombotic complications in certain patients. Over the years the spectrum of disease for which long-term oral anticoagulation is recommended has widened (British Medical,Journal, 1972; Rogers and Sherry, 1976; Staffurth et al., 1977) . The therapeutic objective of achieving the lowest possible rate of thromboembolic complications must be weighed against the risk of haemorrhagic complications of therapy. The present study reviews the haemorrhagic complications of anticoagulation experienced in one anticoagulant clinic over a 7-year period.
Series and methods
In all, 509 outpatients attended between September 1970 and September 1977. Of these, 501 (242 men and 259 women) had case records available for Received for publication 29 December 1978 examination-including 234 attending at the time the study was terminated-and form the basis of this analysis. Two hundred and forty-eight patients were interviewed personally. Four hundred and eighty patients (96%) were maintained on warfarin and 21 (4%) on dindevan. Prothrombin estimations (prothrombin ratio) were measured by the modified Quick test using British comparative thromboplastin (Dacie and Lewis, 1975) . A case:control prothrombin ratio (PTR) between 1 8 and 2-6 to 1 was considered the desirable therapeutic range.
A significant haemorrhagic complication was defined as one in which a patient sought medical advice and received treatment, excepting minor bruising and minor epistaxes which are irregularly reported and therefore not included in this analysis. Significant haemorrhages were grouped into those episodes that were life-threatening (namely intracranial haemorrhage, haematemesis and melaena, and major retroperitoneal haemorrhage) and those which were not (see Table 2 ).
The probability of bleeding was calculated for each year-interval as the number of episodes of bleeding during each year-interval divided by the total number of years of exposure to anticoagulants during each year. Table 1 gives details of the indications for anticoagulation. Valvular heart disease and a prosthesis were the commonest indications for long-term treatment accounting for 61 per cent of the series. The mean duration of treatment per patient was 2-4 years (range 1 month to 7 years) and, in all, 1199 patient-years of treatment were assessed. The mean age (and standard deviation) of men was 54.3 ( ± 9 7) years and of women 55-3 (± 106) years. A mean of 12-5 prothrombin estimations was measured per annum for each patient.
Results

FREQUENCY OF HAEMORRHAGE
Fifty-one significant haemorrhagic complications occurred in 41 patients, 24 in 19 men and 27 in 22 women. The overall incidence of haemorrhagic complications was thus 8&2 per cent among patients (501 patients; 41 patients haemorrhage) and 4-3 per cent per patient-treatment-year (51 haemorrhages in of patients who bled was 47-8 (± 11-5) years for men and 53-6 (± 10-6) years for women, neither significantly different from the means for patients who did not bleed: 54-9 (±9-5) for men and 55 4 (± 10.5) for women. Forty-nine weeks of in-patient hospital care were required for the management of these patients, the mean duration of stay being just under 9 days.
The mean duration of anticoagulant treatment at the time of haemorrhage was 24 ( ± 2 4) years formen and 2X9 (±2.1) years for women. To investigate whether anticoagulants had a durational effect, as far as the risk of haemorrhage was concerned, the probability of bleeding was calculated for each yearly interval for patients starting anticoagulants after 1970 (Fig. 1 ). There was no evidence of a cumulative effect over the first 3 years but some evidence of increasing risk between 4 and 7 years. Though the number of patient-years of treatment assessed for each year interval and shown in brackets decreases, the overall probability ofhaemorrhage in the first 3 years (0{04 ± 0 007) was less (P < 0-01) than the risk between 4 and 7 years (0-10 ± 0.025).
Two deaths were directly attributed to anticoagulants. One occurred in a 61-year-old woman (on warfarin for 10 months because of a mitral valve prosthesis) who became drowsy and later uncon- The success of control of anticoagulant treatment was assessed for each patient as the number of prothrombin estimations within the therapeutic range expressed as a percentage of the total estimations performed on that patient. Fig. 2 shows the percentage frequency of prothrombin ratios within the therapeutic range for patients with and without haemorrhage plotted against the percentage of patients in each group. Control had been less good in those who bled, with higher percentages in the histograms to the left indicating poor control; 62-5 per cent of prothrombin estimations were within the therapeutic range in 'bleeders' compared with 701 per cent in 'non-bleeders', a highly significant difference (P < 0.001) in view of the large number of prothrombin ratios performed. Table 3 shows the prothrombin ratios at the time of haemorrhage. Approximately half of all episodes occurred with the prothrombin ratio within the therapeutic range, but in 23 out of 24 episodes of life-threatening haemorrhage the prothrombin ratio was abnormally high. In contrast the prothrombin ratio was known to be prolonged beyond the therapeutic range in only 1 of the 27 occasions with less serious haemorrhage. Thus maintenance of the prothrombin ratio within the therapeutic range is almost always a protection against life-threatening haemorrhage but not less serious bleeding. Haemorrhage, however, did not always occur with an excessively prolonged prothrombin ratio. A prothrombin ratio greater than 3-4:1 was recorded overall in 2-5 per cent of patients who did not bleed.
In only 18 (35%) out of the 51 haemorrhagic episodes was a probable contributory factor for haemorrhage identified (Table 4) . Drug induced haemorrhage was common, with aspirin or aspirincontaining compounds the most frequent offenders. An intrinsic gastrointestinal lesion (Crohn's disease, small bowel polyp, gastric carcinoma, and duodenal ulcer) was identified in 4 out of the 12 episodes of gastrointestinal bleeding. 
Discussion
During the 1950's the use of oral anticoagulants was more controversial than it is today (Gilchrist and Tulloch, 1956) (Pollard et al., 1962; Coon and Willis, 1974) . Age alters the clinical response to anticoagulants (O'Reilly and Aggeler, 1970; Hewick et al., 1975; Husted and Andreasen, 1977) , either through a reduction in plasma protein binding or depression of hepatic synthesis of clotting factors. However, provided patient compliance and understanding are good and appropriate adjustments of dosage are made, age need not constitute a hazard in treatment and should not by itself be regarded as a contraindication to use. Patients with valve prostheses consequent on rheumatic heart disease accounted for most of the group reported here. Such patients are at risk from periodic, sometimes prolonged, hepatic congestion which can profoundly impair drug catabolism and delay clotting factor synthesis (Hewick et al., 1975) . This may in part explain the different responses to oral anticoagulants at different times in the same patient.
The use of factor concentrate (factors II, VII, IX, X) in the management of haemorrhage from excess oral anticoagulation has advantages over vitamin Ki (Tabemer et al., 1976) and has been a significant advance in reducing the mortality and morbidity of these drugs. Factor concentrate has been freely available in this region for the past 3 or 4 years and allows immediate controlled reversal of anticoagulation without prejudicing later reintroduction of anticoagulant drugs.
Three groups of patients have been identified in whom the risk of haemorrhage is greatest. The first group are those patients in whom the prothrombin ratio has proved difficult to control from the outset; the second group are men with aortic valve prostheses, and the third are patients after 3 years on long-term treatment. Anticoagulants do carry a significant risk of haemorrhage and their long-term use in any patient should be based on firm evidence of efficacy. It is in the 3 groups mentioned that prothrombin control and patient education call for the closest attention, with frequent assessment of dosage. Patients with stable prothrombin ratios have a low risk of major bleeding and may be assessed less frequently. 
